<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983238</url>
  </required_header>
  <id_info>
    <org_study_id>BYON5667.002</org_study_id>
    <nct_id>NCT04983238</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Trial With a Single Arm run-in Period to Evaluate the Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Byondis B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Byondis B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in&#xD;
      period is to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to&#xD;
      reduce ocular toxicity in cancer patients treated with the antibody-drug conjugate (ADC)&#xD;
      SYD985&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter trial has a single arm run-in period followed by a randomized,&#xD;
      placebo-controlled, double-blind comparative part. In the single arm part of the trial,&#xD;
      patients with HER2-expressing locally advanced or metastatic solid tumours will be enrolled&#xD;
      and treated with the antibody-drug conjugate (ADC) SYD985 once every 3 weeks until disease&#xD;
      progression or unacceptable toxicity. All patients will receive concomitant BYON5667 eye&#xD;
      drops. When the primary safety and efficacy analysis of the BYON5667 eye drops at Day 63 is&#xD;
      favorable, the trial may continue to the comparative part in which patients with locally&#xD;
      advanced or metastatic HER2-positive breast cancer will be treated with SYD985. Patients will&#xD;
      be randomly assigned (1:1) to receive BYON5667 or placebo eye drops.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of BYON5667 eye drops by assessing the percentage of patients with SYD985-related ocular adverse events Grade &gt;=1 at Day 63</measure>
    <time_frame>63 days</time_frame>
    <description>Percentage of patients with SYD985-related ocular toxicity Grade ≥1 at Day 63</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular toxicity</measure>
    <time_frame>Day 63 or Day 126</time_frame>
    <description>Percentage of patients with SYD985-related ocular toxicity of different grades at Day 63 or Day 126</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of BYON5667 eye drops by means of Eye Drop Tolerability questionnaire scores</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Tolerability of BYON5667 eye drops Questionnaire includes 5 questions with score of 0 (no discomfort) to 10 (most imaginable discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute Visual Function Questionnaire (NEI VFQ-25) scores</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Self-reported validated questionnaire including 25 questions with scores of 1 to maximum 6, from best/worst to worst/best depending on the question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SYD985-related ocular adverse events (AE)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to first SYD985-related ocular AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation due to SYD985-related ocular toxicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of patients discontinued due to SYD985-related ocular toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SYD985 by assessing the objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Efficacy of SYD985</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SYD985 by assessing the progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Efficacy of SYD985</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SYD985 by assessing the overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Efficacy of SYD985</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of SYD985 by assessing incidence and severity of treatment-emergent drug-related adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Safety of SYD985</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BYON5667 &amp; SYD985</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYON5667 eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; SYD985</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYON5667 &amp; SYD985</intervention_name>
    <description>Ocular administration: BYON5667, Intravenous administration: SYD985</description>
    <arm_group_label>BYON5667 &amp; SYD985</arm_group_label>
    <other_name>BYON5667: sodium thiosulfate</other_name>
    <other_name>SYD985: (vic-)trastuzumab duocarmazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo &amp; SYD985</intervention_name>
    <description>Ocular administration: Placebo, Intravenous administration: SYD985</description>
    <arm_group_label>Placebo &amp; SYD985</arm_group_label>
    <other_name>SYD985: (vic-)trastuzumab duocarmazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age ≥18 years at the time of signing first informed consent;&#xD;
&#xD;
          2. Patient with histologically-confirmed, unresectable locally advanced or metastatic&#xD;
             cancer with the following restriction:&#xD;
&#xD;
             Single arm part: patient with solid tumours of any origin (excluding gastric tumours&#xD;
             and adenocarcinomas of the gastroesophageal junction) who has progressed on standard&#xD;
             therapy or for whom no standard therapy exists; Randomized part: patient with breast&#xD;
             cancer who had either progression during or after at least two human epidermal growth&#xD;
             factor receptor 2 (HER2)-targeting treatment regimens for locally advanced or&#xD;
             metastatic disease, or progression during or after [ado-]trastuzumab emtansine&#xD;
             treatment for locally advanced or metastatic disease;&#xD;
&#xD;
          3. HER2 tumour status as determined by a local laboratory using immunohistochemistry&#xD;
             (IHC) and/or in situ hybridization (ISH):&#xD;
&#xD;
             Single arm part: at least IHC 1+; Randomized part: IHC 3+ and/or ISH positive;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;&#xD;
&#xD;
          5. Patient should refrain from wearing any kind of contact lenses during trial treatment;&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Current or previous use of prohibited medication as listed in the protocol&#xD;
&#xD;
          2. History of infusion-related reactions and/or hypersensitivity to trastuzumab&#xD;
             containing treatment or excipients of the trial treatments which led to permanent&#xD;
             discontinuation of the treatment;&#xD;
&#xD;
          3. History or presence of keratitis;&#xD;
&#xD;
          4. Left ventricular ejection fraction (LVEF) &lt; 50%, or a history of clinically&#xD;
             significant decrease in LVEF during previous trastuzumab containing treatment leading&#xD;
             to permanent discontinuation of treatment;&#xD;
&#xD;
          5. History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.&#xD;
             bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest CT scan;&#xD;
&#xD;
          6. History or presence of clinically significant cardiovascular disease;&#xD;
&#xD;
          7. Severe, uncontrolled systemic disease;&#xD;
&#xD;
          8. Symptomatic brain metastases, brain metastases requiring steroids to manage symptoms,&#xD;
             or treatment for brain metastases within 8 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Mommers, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Byondis B.V., The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Mommers, PhD</last_name>
    <phone>+31(0) 24 679 5100</phone>
    <email>clinicaltrials@byondis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanya Vermaas, MSc</last_name>
    <phone>+31(0)24 679 5100</phone>
    <email>clinicaltrials@byondis.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toxic Optic Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

